Although the increased HER2 expression on CD14+ or CD56+ cells was not robustly correlated with reduced HER2 cancer cell expression, the diversity in response suggests that trogocytosis has the potential to be used as a predictive marker for trastuzumab-based treatment efficacy in breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.